LESI	JE Z.	BENET
LLDL	<u></u>	

	Page 1
1	UNITED STATES PATENT AND TRADEMARK OFFICE
2	BEFORE THE PATENT TRIAL AND APPEAL BOARD
3	
4	APOTEX INC., APOTEX CORP., ARGENTUM PHARMACEUTICALS
	LLC, ACTAVIS ELIZABETH LLC, TEVA
5	PHARMACEUTICALS USA, INC., SUN PHARMACEUTICALS
	INDUSTRIES LTD., SUN PHARMACEUTICAL INDUSTRIES,
6	INC., AND SUN PHARMA GLOBAL FZE,
7	Petitioners,
8	vs.
9	NOVARTIS A.G.,
10	Patent Owner.
11	
12	IPR2017-00854
	Patent No. 9,187,405
13	
14	
15	
16	VIDEOTAPED DEPOSITION OF LESLIE Z. BENET, Ph.D.
17	San Francisco, California
18	Tuesday, March 13, 2018
19	
20	
21	
22	REPORTED BY:
23	REBECCA L. ROMANO, RPR, CSR No. 12546
24	
25	
2	Veritext Legal Solutions 212-279-9424 www.veritext.com 212-490-343

Anotex v. Novartis

Page 2 UNITED STATES PATENT AND TRADEMARK OFFICE	Page 1 APPEARANCES OF COUNSEL (cont'd)
2 BEFORE THE PATENT TRIAL AND APPEAL BOARD	2
	3
4 APOTEX INC., APOTEX CORP., ARGENTUM PHARMACEUTICALS	4 ALSO PRESENT:
LLC, ACTAVIS ELIZABETH LLC, TEVA	5 Tyler Liu, Argentum Pharmaceuticals, LLC(via
5 PHARMACEUTICALS USA, INC., SUN PHARMACEUTICALS INDUSTRIES LTD., SUN PHARMACEUTICAL INDUSTRIES,	6 telephone)
6 INC., AND SUN PHARMA GLOBAL FZE,	7 Brandon Miller, Videographer
7 Petitioners,	8
8 vs.	9
9 NOVARTIS A.G.,	10
10 Patent Owner.	11
11	12
12 IPR2017-00854	12
Patent No. 9,187,405	
13	14
14	15
15	16
16	17
17 VIDEOTAPED DEPOSITION OF LESLIE Z. BENET,	18
18 Ph.D., taken on behalf of the Patent Owner, at	19
19 Wilson Sonsini Goodrich & Rosati, One Market Plaza,	20
20 Spear Tower, Suite 3300, San Francisco, California,	21
21 commencing at 9:38 a.m., March 13, 2018 before	22
22 Rebecca L. Romano, Certified Shorthand Reporter	23
23 No. 12546	24
24	25 /////
25	
Page 3	Page
1 APPEARANCES OF COUNSEL	1 INDEX
2	2 DEPONENT EXAMINATION
3 For the Petitioner - Apotex Inc., Apotex Corp.:	3 LESLIE Z. BENET, PH.D. PAGE
4 WILSON SONSINI GOODRICH & ROSAT	I 4
5 BY: JAD A. MILLS	5 BY MR. TRENCHARD 9
6 Attorney at Law	6 BY MR. MILLS 56
7 701 Fifth Avenue	7
8 Suite 5100	8
9 Seattle, Washington 98104-7036	9 PREVIOUSLY MARKED EXHIBITS
10 (206) 883-2554	10 NUMBER PAGE
11 jmills@wsgr.com	11 Exhibit 1047 21
12	
	12
13 For the Patent Owner - Novartis A.G.:	13 Exhibit 1048 47
14 GIBSON, DUNN & CRUTCHER LLP	14
15 BY: ROBERT W. TRENCHARD	15
16 BY: JANE M. LOVE(via telephone)	16
17 Attorneys at Law	17
18 200 Park Avenue	18
19 New York, New York 10166-0193	19
20 (212) 351-4000	20
21 rtrenchard@gibsondunn.com	21
	22
-	
22 jlove@gibsondunn.com	
22 jlove@gibsondunn.com23	23
22 jlove@gibsondunn.com	

	Page 6 Page
1 San Francisco, California; Tuesday, March 13, 2	
2 9:38 a.m.	2 MR. LIU: Tyler Liu on behalf of
3000	3 Argentum Pharmaceuticals.
	4 THE VIDEOGRAPHER: Thank you. You may
5 THE VIDEOGRAPHER: Good morning.	
6 going on the record at 9:38 a.m. on	6 THE REPORTER: If you could raise your
7 March 13th, 2018.	7 right hand for me, please.
8 Please note the microphones are	8 THE DEPONENT: (Complies.)
9 sensitive, may pick up whispering, private	9 THE REPORTER: You do solemnly state,
10 conversations and cellular interference. Please	10 under penalty of perjury, that the testimony you
11 silence all cell phones and place them away from	
12 the microphones as they interfere with deposition	_
13 audio.	13 THE DEPONENT: I do.
14 Audio and video recording will continue	14
15 to take place unless all parties agree to go off	15
16 the record. This is media No. 1 of the	16
17 video-recorded deposition of Dr. Leslie Benet	17
18 Benet.	18
19 THE DEPONENT: Benet, but I'll go by	19
20 either name.	20
21 MR. TRENCHARD: That one's a more Fi	
22 name.	22
23 THE VIDEOGRAPHER: In the matter of	
24 Apotex, Incorporated, et al., versus Novartis AG	
25 filed in United States Patent and Trademark Offi	ce 25
	Page 7 Page
1 before the Patent Trial and Appeal Board.	1 LESLIE Z. BENET, Ph.D.,
2 Case No. IPR2017-00854.	2 having been administered an oath, was examined and
3 This deposition is being held at	3 testified as follows:
4 One Market Plaza, Spear Tower, Suite 3300,	
5 San Francisco, California.	5 EXAMINATION
6 My name is Brandon Miller from	6 BY MR. TRENCHARD:
7 Veritext Legal Solutions and I'm the videographe	
8 The court reporter is Rebecca Romano from the	-
9 of Veritext Legal Solutions.	9 Q. Thank you very much for coming today.
10 I'm not related to any parties in this	10 As you just heard, my name is
I action nor am I tingnotally interacted in the	
11 action nor am I financially interested in the	11 Bob Trenchard. I'm with Gibson Dunn & Crutcher and
12 outcome.	11 Bob Trenchard. I'm with Gibson Dunn & Crutcher and12 I represent Novartis.
12 outcome.13 Counsel and all present in the room, and	 Bob Trenchard. I'm with Gibson Dunn & Crutcher and I represent Novartis. You understand you're under oath today,
 12 outcome. 13 Counsel and all present in the room, and 14 everyone attending remotely, will please state 	 11 Bob Trenchard. I'm with Gibson Dunn & Crutcher and 12 I represent Novartis. 13 You understand you're under oath today, 14 of course?
 outcome. Counsel and all present in the room, and everyone attending remotely, will please state their appearances and affiliations for the record. 	 11 Bob Trenchard. I'm with Gibson Dunn & Crutcher and 12 I represent Novartis. 13 You understand you're under oath today, 14 of course? 15 A. I do.
 outcome. Counsel and all present in the room, and everyone attending remotely, will please state their appearances and affiliations for the record. MR. MILLS: This is Jad Mills with the 	 11 Bob Trenchard. I'm with Gibson Dunn & Crutcher and 12 I represent Novartis. 13 You understand you're under oath today, 14 of course? 15 A. I do. 16 Q. Is there anything that would interfere
 outcome. Counsel and all present in the room, and everyone attending remotely, will please state their appearances and affiliations for the record. MR. MILLS: This is Jad Mills with the law firm Wilson Sonsini Goodrich & Rosati 	 11 Bob Trenchard. I'm with Gibson Dunn & Crutcher and 12 I represent Novartis. 13 You understand you're under oath today, 14 of course? 15 A. I do. 16 Q. Is there anything that would interfere 17 with your ability to give complete and truthful
 outcome. Counsel and all present in the room, and everyone attending remotely, will please state their appearances and affiliations for the record. MR. MILLS: This is Jad Mills with the law firm Wilson Sonsini Goodrich & Rosati representing Apotex, Inc., and Apotex Corp., and 	11Bob Trenchard. I'm with Gibson Dunn & Crutcher and 12 I represent Novartis.13You understand you're under oath today, 14 of course?15A. I do.16Q. Is there anything that would interfere 17 with your ability to give complete and truthful 18 testimony today?
 outcome. Counsel and all present in the room, and everyone attending remotely, will please state their appearances and affiliations for the record. MR. MILLS: This is Jad Mills with the law firm Wilson Sonsini Goodrich & Rosati representing Apotex, Inc., and Apotex Corp., and here with Dr. Benet. 	 11 Bob Trenchard. I'm with Gibson Dunn & Crutcher and 12 I represent Novartis. 13 You understand you're under oath today, 14 of course? 15 A. I do. 16 Q. Is there anything that would interfere 17 with your ability to give complete and truthful 18 testimony today? 19 A. No.
 outcome. Counsel and all present in the room, and everyone attending remotely, will please state their appearances and affiliations for the record. MR. MILLS: This is Jad Mills with the law firm Wilson Sonsini Goodrich & Rosati representing Apotex, Inc., and Apotex Corp., and here with Dr. Benet. MR. TRENCHARD: Robert Trenchard fr 	11Bob Trenchard. I'm with Gibson Dunn & Crutcher and 12 I represent Novartis.13You understand you're under oath today, 14 of course?15A. I do.16Q. Is there anything that would interfere 17 with your ability to give complete and truthful 18 testimony today?19A. No.20Q. Okay. Are you on any medication that
 outcome. Counsel and all present in the room, and everyone attending remotely, will please state their appearances and affiliations for the record. MR. MILLS: This is Jad Mills with the law firm Wilson Sonsini Goodrich & Rosati representing Apotex, Inc., and Apotex Corp., and here with Dr. Benet. MR. TRENCHARD: Robert Trenchard fr law firm of Gibson Dunn & Crutcher. And with 	11Bob Trenchard. I'm with Gibson Dunn & Crutcher and 1212I represent Novartis.13You understand you're under oath today, 14 of course?14of course?15A. I do.16Q. Is there anything that would interfere 17 with your ability to give complete and truthful18testimony today?19A. No.20Q. Okay. Are you on any medication that 21 affects your memory or perception?
 outcome. Counsel and all present in the room, and everyone attending remotely, will please state their appearances and affiliations for the record. MR. MILLS: This is Jad Mills with the law firm Wilson Sonsini Goodrich & Rosati representing Apotex, Inc., and Apotex Corp., and here with Dr. Benet. MR. TRENCHARD: Robert Trenchard fr law firm of Gibson Dunn & Crutcher. And with the phone is my partner, Dr. Jane Love, also with 	11Bob Trenchard. I'm with Gibson Dunn & Crutcher and 12 I represent Novartis.13You understand you're under oath today, 14 of course?15A. I do.16Q. Is there anything that would interfere 17 with your ability to give complete and truthful 18 testimony today?19A. No.19A. No.20Q. Okay. Are you on any medication that 21 affects your memory or perception? an22A. I am not.
 12 outcome. 13 Counsel and all present in the room, and 14 everyone attending remotely, will please state 15 their appearances and affiliations for the record. 16 MR. MILLS: This is Jad Mills with the 17 law firm Wilson Sonsini Goodrich & Rosati 18 representing Apotex, Inc., and Apotex Corp., and 19 here with Dr. Benet. 20 MR. TRENCHARD: Robert Trenchard fr 21 law firm of Gibson Dunn & Crutcher. And with 22 the phone is my partner, Dr. Jane Love, also with 23 Gibson Dunn & Crutcher. We represent the pate 	11Bob Trenchard. I'm with Gibson Dunn & Crutcher and 12 I represent Novartis.13You understand you're under oath today, 14 of course?15A. I do.16Q. Is there anything that would interfere 17 with your ability to give complete and truthful 18 testimony today?19A. No.com the me on 10Q. Okay. Are you on any medication that 21 affects your memory or perception? 22A. I am not.23Q. Okay. When was the last time you
 12 outcome. 13 Counsel and all present in the room, and 14 everyone attending remotely, will please state 15 their appearances and affiliations for the record. 16 MR. MILLS: This is Jad Mills with the 17 law firm Wilson Sonsini Goodrich & Rosati 18 representing Apotex, Inc., and Apotex Corp., and 19 here with Dr. Benet. 20 MR. TRENCHARD: Robert Trenchard fr 21 law firm of Gibson Dunn & Crutcher. And with 22 the phone is my partner, Dr. Jane Love, also with 	11Bob Trenchard. I'm with Gibson Dunn & Crutcher and 12 I represent Novartis.13You understand you're under oath today, 14 of course?15A. I do.16Q. Is there anything that would interfere 17 with your ability to give complete and truthful 18 testimony today?19A. No.20Q. Okay. Are you on any medication that 21 affects your memory or perception?an22A. I am not.cmt23Q. Okay. When was the last time you 24 consumed alcohol?

-	
Page 1	-
1 Q. The effects have clearly worn off by 2 then?	1 Q. Okay. So I'd like to just go through
	2 each of those categories a little bit, starting
3 A. Maybe.	3 with the first one. And I'm asking you for an
4 Q. Okay. Fair enough.	4 approximation because I realize that you've had a
5 So we'll get to your experience in a	5 long career.
6 second. I gather you've been through this drill	6 Approximately how many times have you
7 several times before. But just for the sake of the	7 submitted written testimony in a case?
8 record, allow me to make a few things clear.	8 A. Wow. Probably more than 150 times.
9 First, of course, your answers today must	9 Q. And have all of those always been as an
10 be verbal, in the form of words, rather than grunts	10 expert?
11 or nods.	11 A. No. No.
12 Do you understand?	12 Q. So have you submitted written testimony
13 A. I understand.	13 as a direct witness on on occasion?
14 Q. Thank you.	14 A. Yes.
15 We will try to take breaks probably every	15 Q. Okay. How many times have you done that?
16 hour or so. If at any point you need a break, just	16 A. Once.
17 let me know, and subject to maybe finishing a few	17 Q. What sort of case was that?
18 questions, I'm happy to try to accommodate you.	18 A. University issue with a professor.
19 Okay?	19 Q. Understood.
20 A. Thank you.	20 Other than that one time, have all of
21 Q. I'll be asking questions today. If you	21 your other instances of submitting written
22 don't understand one of my questions, please don't	22 testimony been as an expert?
23 hesitate to tell me and we'll work it out and try	23 A. Yes.
24 to figure out a way that you can understand.	24 Q. And that's an expert in pharmacology?
25 Okay?	25 A. Yes.
Page 1	Page 1:
1 A. Thank you. Yes.	1 Q. Have you submitted this written testimony
2 Q. And, of course, if you if you don't	2 in strike that.
3 tell me that there's some ambiguity or problem with	3 Do you have a strike that again.
4 my question, I'm going to assume that you do	4 Do you know what courts or bodies the
5 understand them. But as I said, we'll work through	5 cases were pending in front of?
6 any complications with language along the way.	6 A. Every.
7 Okay?	7 Q. Every.
8 A. I understand.	8 A. Every U.S. and Europe.
9 Q. Okay. So I gather you have participated	9 Q. Fair enough.
10 as an expert in other litigations before; is that	10 So U.S. state court proceedings?
11 right?	11 A. Yes.
12 A. That's correct.	12 Q. U.S. federal court proceedings?
	· · · ·
13 Q. And you've provided testimony in those	13 A. Yes.
14 other cases?	14 Q. Proceedings in the patent office?
14 other cases? 15 A. I have.	14 Q. Proceedings in the patent office?15 A. Yes.
 14 other cases? 15 A. I have. 16 Q. Has that testimony been in the form of 	 14 Q. Proceedings in the patent office? 15 A. Yes. 16 Q. Proceedings in a European forum?
 14 other cases? 15 A. I have. 16 Q. Has that testimony been in the form of 17 writing, such as a declaration or aff 	 Q. Proceedings in the patent office? A. Yes. Q. Proceedings in a European forum? A. Yes.
 14 other cases? 15 A. I have. 16 Q. Has that testimony been in the form of 17 writing, such as a declaration or aff 18 affidavit? 	 14 Q. Proceedings in the patent office? 15 A. Yes. 16 Q. Proceedings in a European forum? 17 A. Yes. 18 Q. What sort of European forum?
 14 other cases? 15 A. I have. 16 Q. Has that testimony been in the form of 17 writing, such as a declaration or aff 18 affidavit? 19 A. Yes, it is. 	 Q. Proceedings in the patent office? A. Yes. Q. Proceedings in a European forum? A. Yes. Q. What sort of European forum? A. The equivalent to the what this
 14 other cases? 15 A. I have. 16 Q. Has that testimony been in the form of 17 writing, such as a declaration or aff 18 affidavit? 19 A. Yes, it is. 20 Q. Has it also been in the form of 	 14 Q. Proceedings in the patent office? 15 A. Yes. 16 Q. Proceedings in a European forum? 17 A. Yes. 18 Q. What sort of European forum? 19 A. The equivalent to the what this 20 this patent type of process in Europe.
 14 other cases? 15 A. I have. 16 Q. Has that testimony been in the form of 17 writing, such as a declaration or aff 18 affidavit? 19 A. Yes, it is. 20 Q. Has it also been in the form of 21 deposition testimony, like what we're doing right 	 14 Q. Proceedings in the patent office? 15 A. Yes. 16 Q. Proceedings in a European forum? 17 A. Yes. 18 Q. What sort of European forum? 19 A. The equivalent to the what this 20 this patent type of process in Europe. 21 Q. Does the term European opposition sound
 14 other cases? 15 A. I have. 16 Q. Has that testimony been in the form of 17 writing, such as a declaration or aff 18 affidavit? 19 A. Yes, it is. 20 Q. Has it also been in the form of 21 deposition testimony, like what we're doing right 22 now? 	 14 Q. Proceedings in the patent office? 15 A. Yes. 16 Q. Proceedings in a European forum? 17 A. Yes. 18 Q. What sort of European forum? 19 A. The equivalent to the what this 20 this patent type of process in Europe. 21 Q. Does the term European opposition sound 22 familiar?
 14 other cases? 15 A. I have. 16 Q. Has that testimony been in the form of 17 writing, such as a declaration or aff 18 affidavit? 19 A. Yes, it is. 20 Q. Has it also been in the form of 21 deposition testimony, like what we're doing right 22 now? 23 A. It has. 	 14 Q. Proceedings in the patent office? 15 A. Yes. 16 Q. Proceedings in a European forum? 17 A. Yes. 18 Q. What sort of European forum? 19 A. The equivalent to the what this 20 this patent type of process in Europe. 21 Q. Does the term European opposition sound 22 familiar? 23 A. That's correct.
 14 other cases? 15 A. I have. 16 Q. Has that testimony been in the form of 17 writing, such as a declaration or aff 18 affidavit? 19 A. Yes, it is. 20 Q. Has it also been in the form of 21 deposition testimony, like what we're doing right 22 now? 	 14 Q. Proceedings in the patent office? 15 A. Yes. 16 Q. Proceedings in a European forum? 17 A. Yes. 18 Q. What sort of European forum? 19 A. The equivalent to the what this 20 this patent type of process in Europe. 21 Q. Does the term European opposition sound 22 familiar?

1Q. And how many times have you submitted2written testimony before the U.S. Patent Office?A. In U.S.?3A. It's so let me clarify that. It'sQ. In the U.S.4only for these type of procedures that we're doing55today.Q. In the U.S.6Q. Let's just start more broadly and then77we'll we'll narrow it down.58So more broadly, how often have you99submitted written testimony to the910U.S. Patent Office?811A. I'm on treally sure whether it did. 1 - 1 know for1312not really sure whether it did. 1 - 1 know for1313sure this is the second U.S. case under this1414format.1515Q. By "this format," you mean an IPR?1616A. IPR, yes.1617Q. And what did you submit testimony in that19GW Pharmaceuticals.1821case?2222A. And without going into any confidential24information, could you just generally describe the25subject matter of your testimony?29Q. And without going into any confidential24pharmacology expert?3A. It's not settled.3Q. I's not.3Q. No thaw a patent issue.4a pharmacology expert?5A. I's not settled.10A. It's not settled.11Q. Were you deposed in that case?<				
2 written testimony before the U.S. Patent Office? 3 A. It's so let me clarify that. It's 3 A. It's so let me clarify that. It's 4 A. Not that I recall. 4 only for these type of procedures that we're doing 5 Q. In the U.S. 4 only for these type of procedures that we're doing 5 Q. Do you recall submitting any declaration 6 Q. Let's just start more broadly and then 7 A. It's so low orecall submitting any declaration 6 Q. Let's just start more broadly, how often have you 8 A. I I don't recall. It's a long time 9 submitted written testimony to the 10 Q. Fair enough. 11 11 A. Ir R, yes. 10 Q. Fair enough. 11 13 surtent estimony in district court? 14 A. It's really hard for me to to state 15 Q. By "this format." you mean an IPR? 16 A. It's really hard for me to to state 15 Q. And what was the first one? 12 A. It's really hard for me to to state 17 Versus fields.1 1 1 don't know. 18 Q. Fair enough. 12 case yutice state of your testimony? 22 A. Several times. 24 Q. And what are the other nine,	1		1	Page 10
3 A. It's so let me clarify that. It's 3 Q. In the U.S. 4 only for these type of procedures that we're doing 5 today. A. Not that I recall. 6 Q. Let's just start more broadly and then 7 we'll - we'll narrow it down. 5 7 We'll - we'll narrow it down. 8 A. To tome broadly, how often have you 9 submitted written testimony to the 9 ago. 8 A. I - I don't recall. It's a long time 10 U.S. Patent Office? 10 Q. Fair enough. 11 So upst returning to federal district 12 nor really sure whether it did. I - I know for 13 written testimony in district court? 14 format. 15 Go appreciate it's a long time. 16 15 Q. And what was the first one? 14 A. It's really hard for me to - to - state 17 Q. And whan did you submit testimony in that 15 do appreciate it's a long time. 16 A. It's as a patent issue. 22 A. Probably in May of last year. 23 23 Q. And when did you submit testimony? 24 Q. And what are the other nine, other than 24 paparmacology expert? 24 A. No, hiw wa				• •
4 only for these type of procedures that we're doing 4 A. Not that I recall. 5 today. Q. Do you recall submitting any declaration 6 Q. Let's just start more broadly and then 7 7 we'll - we'll narrow it down. 8 8 So more broadly, how often have you 8 9 submitted written testimony to the 9 10 U.S. Patent Office? 11 11 A. Tm not really sure because that Im 12 12 not really sure because that Im 13 13 sure this is the second U.S. case under this 14 14 format. 10 Q. Fair enough. 15 Q. By "this format," you mean an IPR? 16 A. Ir's really hard for me to - to - state 17 Q. And what was the first one? 18 A. Ir's main proventicals. 20 Q. And when did you submit testimony in that 21 case? 14 22 A. Probably in May of last year. 23 Q. And what are the other mine, other than 25 woll dy ou submitted testimony? 22 20 And what are the other mine, other than 21 A. It was a patent issue. 2 A.		-		
5 today. 5 Q. Do you recall submitting any declaration of the patent office in connection with acquirin 7 those patents? 8 So more broadly, how often have you 9 submitted written testimony to the 10 Q. Fair enough. 11 A. Tr not really sure because that Tm 10 Q. Fair enough. 11 A. Tr not really sure whether it did. 1 1 know for 13 worth is its the second U.S. case under this 13 sure this is the second U.S. case under this 13 written testimony in district court? 14 A. It was the first one? 16 A. It's cally hard for me to -u -state 17 Q. And what was the first one? 16 A. It's really hard for me to -u -state 19 GW Pharmaccuticals. 19 How many patent cases outside of the 20 Q. And when did you submitt testimony in that 21 case? 22 A. Probably in May of last year. 23 Q. And without going into any confidential 24 uo and what are the other nine, other than 24 D. And whou tissue. 22 A. It was a patent issue. 24 Q. And what are the other nine, other than 25 A. It was a patent issue. 24 Q. And what are the other nine, other than 26		•	-	-
6 Q. Let's just start more broadly and then 6 to the patent office in connection with acquirin 7 we'll we'll narrow it down. 7 those patents? 8 So more broadly, how often have you 9 ago. 9 submitted written testimony to the 9 ago. 10 U.S. Patent Office? 10 Q. Fair enough. 11 A. I'm not really sure because that I'm 11 So just returning to federal district 12 court, federal court, how often have you submit 3 written testimony in district court? 14 format. 10 Q. Fair enough. 11 15 O. By "this format," you mean an IPR? 16 A. It's really hard for me to - to state 17 Q. And what was the first one? 18 A. It was insys Pharmaceuticals versus 19 How many patent cases outside of the 12 og was ubmitted testimony in that 12 asoe? 22 A. Several times. Approximately 150, I 23 would say 140 are patent issue. 24 Q. And what are the other nine, other than 23 wold was that issue. 1 A. We'll, there are some well, actually, to ye osexpert. 4 Q. W				
7 we'll we'll narrow it down. 7 these patents? 8 So more broadly, how often have you 9 submitted written testimony to the 10 U.S. Patent Office? 10 Q. Fair enough. 11 A. Tr not really sure becher it did. 1 I know for 13 So just returning to federal district 12 not really sure whether it did. 1 I know for 13 So just returning to federal district 13 sure this is the second U.S. case under this 14 Again, Tm asking for approximations. I 15 Q. By "this format," you mean an IPR? 16 A. It's really hard for me to - to state 17 Q. And what was the first one? 15 do appreciate it's a long time. 16 A. It was insys Pharmaceuticals versus 19 How many patent cases outside of the 20 Q. And when did you submitt testimony in that 12 case? 2 23 Q. And whitour going into any confidential 24 Warmacology as patent issue. 24 Q. And what are the other nine, other than 23 Q. A patent issue. 1 A. It was a patent issue. 1 A. Well, there are some well, actually, 2 Q. A patent i		•	-	
8 So more broadly, how often have you 9 9 submitted written testimony to the 9 10 U.S. Patent Office? 10 11 A. I'm not really sure because that I'm 11 12 not really sure whether it did. I I know for 13 13 sure this is the second U.S. case under this 11 14 format. 12 15 Q. By "this format," you mean an IPR? 16 16 A. IPR, yes. 11 17 Q. And what was the first one? 14 18 A. It was Insys Pharmaceuticals versus 19 19 GW Pharmaceuticals. 10 20 Q. And when did you submit testimony in that 21 21 case? 22 A. Probably in May of last year. 23 Q. And when did you sub generally describe the 23 west was a patent issue. 24 information, could you just generally describe the 23 west was a patent issue. 25 A. It was a patent issue. 1 A. Well, there are some well, actually, 2 2 Q. And you submitted testimony as a 4 Derast				
9 submitted written testimony to the 9 ago. 10 U.S. Patent Office? 10 Q. Fair enough. 11 A. Irm not really sure because that I'm 10 Q. Fair enough. 12 not really sure whether it did. I I know for 13 sure this is the second U.S. case under this 14 format. So just returning to federal district 15 Q. By "this format," you mean an IPR? 14 Again, I'm asking for approximations. I 16 A. IPR, yes. 16 A. It's really hard for me to to state 17 Q. And what was the first one? 18 A. It was nays Pharmaceuticals versus 19 GW Pharmaceuticals. 19 How many patent cases outside of the 20 Q. And when did you submit testimony in that 21 case? 21 case? 22 A. Probably in May of last year. 23 Q. And without going into any confidential 23 would say 140 are patent issue. 24 information, could you just generally describe the 24 Q. And what are the other nine, other than 25 while that itsue. 24 Q. And what are th other nine, other than 26 A. I twas a patent issue. 1 A. It was a patent issue. 3 And you submitted that testimony as a 4 pharmacology expert? 5 A. I did. 6 Q. Were you deposed in that case? 6 Q. Were you deposed in that case? 7 Q. Product liability?				-
10 U.S. Patent Office? 10 Q. Fair enough. 11 A. Tm not really sure because that Tm 11 So just returning to federal district 12 not really sure whether it did. 1 I know for 13 written testimony in district court? 14 format. 12 court, federal court, how often have you submit 15 Q. By "this format," you mean an IPR? 16 A. If's really hard for me totos state 17 Q. And what was the first one? 16 A. It's really hard for me totos state 17 Q. And when did you submit testimony in that 16 A. It's really hard for me totos state 17 Q. And when did you submit testimony in that 17 versus federal. I I I don't know. 18 A. It was anysy Pharmaccuticals versus 19 How many patent cases outside of the 20 Q. And when did you submit testimony in that 21 case? 22 A. Several times. Approximately 150, I 23 Q. And whithout going into any confidential 24 Q. And what are the other nine, other than 25 A. It was a patent issue. 25 1 A. Well, there are some well, actually, 2 Q. Apatent issu				-
11 A. Tm not really sure because that I'm 11 So just returning to federal district 12 not really sure whether it did. 1- 1 know for 13 sure this is the second U.S. case under this 11 So just returning to federal district 14 format. 12 court, federal court, how often have you submit 14 format. Harmachic court? 14 15 Q. By "this format," you mean an IPR? 16 A. It's really hard for me to to state 16 A. It was Insys Pharmaceuticals versus 16 A. It's really hard for me to to state 17 Q. And when did you submit testimony in that 16 A. It's really hard for me to to state 17 Q. And when did you submit testimony in that 19 How many patent cases outside of the 20 Q. And without going into any confidential 11 21 you submitted testimony? 21 A. It was a patent issue. 22 A. Several times. Approximately 150, I 23 21 A dy ou submitted that testimony as a 1 A. Well, there are some well, actually, 24 2 Q. And what are the other nine, other than 25 because of personal i		-		
12 not really sure whether it did. I – I know for 13 sure this is the second U.S. case under this12 court, federal court, how often have you submit 13 written testimony in district court?14 format.13 written testimony in district court?15 Q. By "this format," you mean an IPR? 16 A. IPR, yes.14 Again, I'm asking for approximations. I 13 do appreciate it's a long time.16 A. IPR, yes.16 A. It's really hard for me to to state 17 versus federal. I I - I don't know.18 A. It was Insys Pharmaceuticals.19 How many pattent cases outside of the 20 Q. And when did you submit testimony in that 21 case?22 A. Probably in May of last year. 23 Q. And without going into any confidential 24 information, could you just generally describe the 25 subject matter of your testimony?24 A. Several times. Approximately 150, I 23 would say 140 are patent issue.24 Q. And what are the other nine, other than 25 that one that was a university issue?24 2 wand what are the other nine, other than 25 that one that was a university issue?25 A. I did.1 A. Was, a patent issue.2 2 the number should be a little lower. 130 mayb 3 because of personal injury type of expert.4 pharmacology expert?6 A. No, this was product.7 Q. Product liability.8 Q. Do you know if that case is still ongoing 9 or has it been resolved?9 Q. Understood. Thank you.10 A. It's not settled.10 So focusing on the one other IPR in what 11 you submitted testimony?12 Do you know it's been decided by the 13 board yet?13 A. I was.14 A. I believe it has not been decided.14 Q. How many declarations did you submitt 15 that?				
13 sure this is the second U.S. case under this 13 written testimony in district court? 14 format. 14 format. 15 Q. By "this format," you mean an IPR? 16 A. If's really hard for me to to state 16 A. It was Insys Pharmaceuticals versus 16 A. It's really hard for me to to state 17 Q. And what was the first one? 16 A. It's really hard for me to to state 17 Q. And what was the first one? 16 A. It's really hard for me to to state 17 Q. And when did you submit testimony in that 21 case? 20 Q. And whon did you submit testimony in that 21 case? 21 case? 22 A. Probably in May of last year. 23 would say 140 are patent issues. 23 Q. And without going into any confidential 24 information, could you just generally describe the 25 would say 140 are patent issue. 24 Q. And what are the other nine, other than 25 that one that was a university issue? 11 A. Well, there are some well, actually, 2 G. A patent issue. 24 Q. Ware you deposed in that case? 14 A. It's not. 14 A. I's not studed. 11 Q. It's not. 15 oo you know it's been decided by the 15 oo you know it's been decided. 16 A. This is the same case as Europe, so it 17 A. I was. 14 A. I believe it has not been decided. 2 How many declarations did you submitt <td></td> <td></td> <th></th> <td></td>				
14 format.14 Again, Tm asking for approximations. I15 Q. By "this format," you mean an IPR?16 A. IPR, yes.16 A. IPR, yes.16 A. It's really hard for me to to state17 Q. And what was the first one?16 A. It's really hard for me to to state18 A. It was Insys Pharmaceuticals versus16 A. It's really hard for me to to state19 GW Pharmaceuticals.16 A. It's really hard for me to to state20 Q. And when did you submit testimony in that21 case?21 case?22 A. Probably in May of last year.23 Q. And without going into any confidential19 How many patent cases outside of the24 information, could you just generally describe the23 would say 140 are patent issues.25 A. I did.24 Q. And what are the other nine, other than26 A. I did.5 type cases?6 A. I did.5 type cases?7 A. I was.9 or has it been resolved?9 or has it been resolved?9 Q. Understood. Thank you.10 A. It's not settled.11 Q. It's not.11 Q. It's not.10 So focusing on the one other IPR in which12 Do you know it's been decided by the13 board yet?13 board yet?13 A. I was.14 A. I believe it has not been decided.14 Q. How many declarations did you submitted testimony?17 A. Three or four.18 I think in the U.S. only one.19 pharmacology?20 A. A. Initially, it was from my own patents,21 but more recently as an expert.21 A. Yes.		•		
15 Q. By "this format," you mean an IPR? 15 do appreciate it's a long time. 16 A. IPR, yes. 16 A. It's really hard for me to to state 17 Q. And what was the first one? 16 A. It's really hard for me to to state 17 Q. And what was the first one? 16 A. It's really hard for me to to state 18 A. It was Insys Pharmaceuticals. 16 A. It's really hard for me to to state 20 Q. And when did you submit testimony in that 16 A. It's really hard for me to to state 20 Q. And when did you submit testimony in that 17 Versus federal. I I I don't know. 21 Q. And whout going into any confidential 20 patent office, in Europe or the United States, ha 21 you submitted itst going into any confidential 23 Q. And whout going into any confidential 24 information, could you just generally describe the 25 A. Several times. Approximately 150, I 23 Q. And what a patent issue. 24 Q. And what are the other nine, other than 25 A. I did. 6 A. Well, there are some well, actually, 2 Q. Apatent issue. 7 A.				
16 A. IPR, yes. 17 Q. And what was the first one? 18 A. It was Insys Pharmaceuticals versus 19 GW Pharmaceuticals. 20 Q. And when did you submit testimony in that 21 case? 22 A. Probably in May of last year. 23 Q. And without going into any confidential 24 information, could you just generally describe the 25 Subject matter of your testimony? 26 A. It was a patent issue. 27 A. Patent issue. 28 Q. Apatent issue. 29 A. Patent issue. 3 And you submitted that testimony as a 4 pharmacology expert? 5 A. I did. 6 Q. Were you deposed in that case? 7 A. I was. 8 Q. Do you know if that case is still ongoing 9 or has it been resolved? 10 A. It's not. 11 Q. How many European patent office 12 Do you know if sheen decided by the 13 board yet? 14 A. Ibelieve it has not been decided. </td <td></td> <td></td> <th></th> <td>• • •</td>				• • •
17Q. And what was the first one?18A. It was Insys Pharmaccuticals versus19GW Pharmaccuticals.20Q. And when did you submit testimony in that21case?22A. Probably in May of last year.23Q. And without going into any confidential24information, could you just generally describe the25subject matter of your testimony?26Q. And what are the other nine, other than27A. It was a patent issue.28Q. A patent issue.29Q. A patent issue.3And you submitted that testimony as4pharmacology expert?5A. I did.6Q. Were you deposed in that case?7A. I was.10A. It's not settled.11Q. It's not.12Do you know if that case is still ongoing9or has it been resolved?10A. It's not settled.11Q. It's not.12Do you know it's been decided.15Q. How many European patent office16porceedings have you submitted testimony?17A. Three or four.18Q. And, again, that was as an expert in19pharmacology?20A. Initially, it was from my own patents,21but more recently as an expert.				
18 A. It was Insys Pharmaceuticals versus 18 Q. Fair enough. 19 GW Pharmaceuticals. 19 How many patent cases outside of the 20 Q. And when did you submit testimony in that 21 case? 20 22 A. Probably in May of last year. 23 Q. And without going into any confidential 24 information, could you just generally describe the 25 would say 140 are patent issues. 25 usit was a patent issue. 24 Q. And what are the other nine, other than 25 ya patent issue. 24 Q. And what are the other nine, other than 26 Q. A patent issue. 24 Q. And what are the other nine, other than 26 A patent issue. 24 Q. And what are the other nine, other than 27 A. It was a patent issue. 24 Q. And what are the other nine, other than 26 Q. A patent issue. 24 Q. And what are the other nine, other than 27 A. It was a patent issue. 24 Q. Was that what medical malpractice 3 badre testimony? 26 A. No, this was product. 7 3 Do you know if that case is still ongoing <td></td> <td></td> <th></th> <td>-</td>				-
19 GW Pharmaceuticals.19 How many patent cases outside of the20 Q. And when did you submit testimony in that21 case?22 A. Probably in May of last year.23 Q. And wihout going into any confidential24 information, could you just generally describe the25 subject matter of your testimony?25 subject matter of your testimony?22 A. Several times. Approximately 150, I23 Q. A patent issue.24 Q. And what are the other nine, other than25 and you submitted that testimony as a1 A. It was a patent issue.3 And you submitted that testimony as a1 A. It was.4 pharmacology expert?5 A. I did.5 A. I did.6 Q. Were you deposed in that case?6 Q. Were you deposed in that case?7 A. I was.9 or has it been resolved?9 Q. Understood. Thank you.10 A. It's not settled.10 So focusing on the one other IPR in whit11 Q. It's not.10 So focusing on the one other IPR in whit12 bo you know it's been decided.12 deposed in that case; is that right?13 board yet?13 A. I was.14 A. I believe it has not been decided.14 Q. How many declarations did you submit15 Q. And, again, that was as an expert in19 pharmacology?19 pharmacology?10 A. Initially, it was from my own patents,21 but more recently as an expert.21 A. Yes.		-		
20Q. And when did you submit testimony in that 21 case?20patent office, in Europe or the United States, he 21 you submitted testimony?22A. Probably in May of last year.21you submitted testimony?23Q. And without going into any confidential 24 information, could you just generally describe the 25 subject matter of your testimony?22A. Several times. Approximately 150, I 23 would say 140 are patent issue.24Q. And what are the other nine, other than 25 that one that was a university issue?25A. It was a patent issue.24Q. And what are the other nine, other than 25 that one that was a university issue?2A. Product issue.24Q. And what are the other nine, other than 25 that one that was a university issue?2A. Several times. Approximately 150, I 23 would say 140 are patent issue.2A. Several times. Approximately 150, I 23 would say 140 are patent issue.2A. Several times. Approximately 150, I 23 would say 140 are patent issue.3And you submitted that testimony as a 4 pharmacology expert?5A. I did.6Q. Were you deposed in that case?7A. I was.8Q. Do you know if that case is still ongoing 9 or has it been resolved?10A. It's not settled.11Q. It's not.12Do you know it's been decided.15Q. How many European patent office16A. This is the same case as Europe, so it17A. Three or four.18Q. And soy ou were you deposed only o		•		
21 case?21 you submitted testimony?22A. Probably in May of last year.23Q. And without going into any confidential24 information, could you just generally describe the25 subject matter of your testimony?26A. Grade and the entities and the				• •
22A. Probably in May of last year.22A. Several times. Approximately 150, I23Q. And without going into any confidential24information, could you just generally describe the24information, could you just generally describe the23would say 140 are patent issues.25subject matter of your testimony?24Q. And what are the other nine, other than25subject matter of your testimony?24Q. And what are the other nine, other than25a. It was a patent issue.24Q. And what are the other nine, other than3And you submitted that testimony as a4harmacology expert?5A. I did.1A. Well, there are some well, actually,6Q. Were you deposed in that case?6A. No, this was product.7A. I was.4Q. Was that what medical malpractice8Q. Do you know if that case is still ongoing9G. Understood. Thank you.10A. It's not settled.10So focusing on the one other IPR in which11Q. It's not.11You submitted testimony?14A. I believe it has not been decided.14Q. How many declarations did you submitted15Q. And, again, that was as an expert in19Q. And so you were you deposed only o19Q. And so you were you deposed only o201120A. Initially, it was from my own patents,21A. Yes.		- • •		
23Q. And without going into any confidential23would say 140 are patent issues.24Q. And what are the other nine, other than25subject matter of your testimony?24Q. And what are the other nine, other than25subject matter of your testimony?24Q. And what are the other nine, other than25and you submitted that suse.24Q. And what are the other nine, other than2Q. A patent issue.24Q. And what are the other nine, other than3And you submitted that testimony as a44pharmacology expert?2the number should be a little lower. 130 mayb3And you submitted that testimony as a34pharmacology expert?4Q. Was that what medical malpractice5A. I did.7Q. Product liability?8Q. Do you know if that case is still ongoing9Q. Understood. Thank you.9or has it been resolved?9Q. Understood. Thank you.10A. It's not.11you submitted testimony you said you were12Do you know it's been decided by the13A. I was.13board yet?13A. I was.14A. I believe it has not been decided.14Q. How many declarations did you submitt15g. How many European patent office16A. This is the same case as Europe, so it16A. Initially, it was from my own patents,18I think in the U.S. only one.19pharmacology?20A. A Yes. <t< td=""><td></td><td></td><th></th><td></td></t<>				
24 information, could you just generally describe the 25 subject matter of your testimony?24Q. And what are the other nine, other than 25 that one that was a university issue?1A. It was a patent issue.251A. Well, there are some well, actually, 2 the number should be a little lower. 130 mayb 3 because of personal injury type of expert.3And you submitted that testimony as a 4 pharmacology expert?1A. Well, there are some well, actually, 2 the number should be a little lower. 130 mayb 3 because of personal injury type of expert.4Q. Ware you deposed in that case?7Q. Was that what medical malpractice 5 type cases?6Q. Were you deposed in that case?7Q. Product liability?8Q. Do you know if that case is still ongoing 9 or has it been resolved?9Q. Understood. Thank you.10A. It's not10So focusing on the one other IPR in which 11 you submitted testimony you said you were12Do you know it's been decided by the 13 board yet?13A. I was.14A. I believe it has not been decided.14Q. How many declarations did you submitt15Q. How many European patent office 16A. This is the same case as Europe, so it 1716A. This is the same case as Europe, so it 171717A. Initially, it was from my own patents, 2119Q. And so you were you deposed only o 2020A. Initially, it was from my own patents, 2121A. Yes.				
25 subject matter of your testimony? 25 that one that was a university issue? Page 15 Page 15 1 A. It was a patent issue. 1 A. Well, there are some well, actually, 2 Q. A patent issue. 1 A. Well, there are some well, actually, 3 And you submitted that testimony as a 4 pharmacology expert? 4 pharmacology expert? 4 Q. Was that what medical malpractice 5 A. I did. 5 type cases? 6 Q. Were you deposed in that case? 7 A. I was. 8 Q. Do you know if that case is still ongoing 9 A. No, this was product. 9 or has it been resolved? 9 Q. Understood. Thank you. 10 A. It's not settled. 10 So focusing on the one other IPR in which 11 Q. It's not. 11 you submitted testimony you said you were 12 Do you know it's been decided by the 13 A. I was. 13 board yet? 13 A. I was. 14 A. I believe it has not been decided. 15 that? 16 proceedings have you submitted testimony? 16 A. This is the same case as Europe, so it 17 A. Three or four. 18 Q. And, again, that was as an expert in 19 pharmacology? 19 Q. And so you were you deposed only o 20 A. Initially, it was from my own patents, 21 A. Yes.			23	
Page 151A. It was a patent issue.2Q. A patent issue.3And you submitted that testimony as a4pharmacology expert?5A. I did.6Q. Were you deposed in that case?7A. I was.8Q. Do you know if that case is still ongoing9or has it been resolved?10A. It's not settled.11Q. It's not.12Do you know it's been decided by the13board yet?14A. I believe it has not been decided.15Q. How many European patent office16proceedings have you submitted testimony?17A. Three or four.18Q. And, again, that was as an expert in19pharmacology?20A. Initially, it was from my own patents,21but more recently as an expert.				-
1A. It was a patent issue.2Q. A patent issue.3And you submitted that testimony as a4pharmacology expert?5A. I did.6Q. Were you deposed in that case?7A. I was.8Q. Do you know if that case is still ongoing9or has it been resolved?10A. It's not settled.11Q. It's not.12Do you know it's been decided by the13board yet?14A. I believe it has not been decided.15Q. How many European patent office16proceedings have you submitted testimony?17A. Three or four.18Q. And, again, that was as an expert in19pharmacology?20A. Initially, it was from my own patents,21but more recently as an expert.	25	subject matter of your testimony?	25	that one that was a university issue?
2Q. A patent issue.3And you submitted that testimony as a4pharmacology expert?5A. I did.6Q. Were you deposed in that case?7A. I was.8Q. Do you know if that case is still ongoing9or has it been resolved?10A. It's not settled.11Q. It's not.12Do you know it's been decided by the13board yet?14A. I believe it has not been decided.15Q. How many European patent office16proceedings have you submitted testimony?17A. Three or four.18Q. And, again, that was as an expert in19pharmacology?20A. Initially, it was from my own patents,21but more recently as an expert.		Page 15		Page 1'
 And you submitted that testimony as a 4 pharmacology expert? 5 A. I did. 6 Q. Were you deposed in that case? 7 A. I was. 8 Q. Do you know if that case is still ongoing 9 or has it been resolved? 10 A. It's not. 11 Q. It's not. 12 Do you know it's been decided by the 13 board yet? 14 A. I believe it has not been decided. 15 Q. How many European patent office 16 proceedings have you submitted testimony? 17 A. Three or four. 18 Q. And, again, that was as an expert in 19 pharmacology? 20 A. Initially, it was from my own patents, 21 but more recently as an expert. 3 because of personal injury type of expert. 4 Q. Was that what medical malpractice 5 type cases? 6 A. No, this was product. 7 Q. Product liability? 8 A. Product liability. 9 Q. Understood. Thank you. 10 So focusing on the one other IPR in which 11 you submitted testimony you said you were 12 deposed in that case; is that right? 13 A. I was. 14 Q. How many declarations did you submitted 15 that? 16 A. This is the same case as Europe, so it 17 A. Initially, it was from my own patents, 21 but more recently as an expert. 3 because of personal injury type of expert. 4 Q. Was that what medical malpractice 5 type case? 6 A. No, this was product. 7 Q. Product liability. 9 Q. Understood. Thank you. 10 So focusing on the one other IPR in which 11 you submitted testimony you said you were 12 deposed in that case; is that right? 13 A. I was. 14 Q. How many declarations did you submitted 15 that? 16 A. This is the same case as Europe, so it 17 gets it gets complicated. 18 I think in the U.S. only one	1	-		-
4 pharmacology expert?4Q. Was that what what medical malpractice5A. I did.5type cases?6Q. Were you deposed in that case?6A. No, this was product.7A. I was.7Q. Product liability?8Q. Do you know if that case is still ongoing9or has it been resolved?9or has it been resolved?9Q. Understood. Thank you.10A. It's not settled.10So focusing on the one other IPR in which11Q. It's not.10So focusing on the one other IPR in which12Do you know it's been decided by the13A. I believe it has not been decided.15Q. How many European patent office14Q. How many declarations did you submitt16A. Three or four.16A. This is the same case as Europe, so it17A. Intree or four.18I think in the U.S. only one.19pharmacology?20A. Initially, it was from my own patents,1921but more recently as an expert.21A. Yes.	2			
5A. I did.5type cases?6Q. Were you deposed in that case?6A. No, this was product.7A. I was.7Q. Product liability?8Q. Do you know if that case is still ongoing9or has it been resolved?9or has it been resolved?9Q. Understood. Thank you.10A. It's not settled.10So focusing on the one other IPR in which11Q. It's not.10So focusing on the one other IPR in which12Do you know it's been decided by the12deposed in that case; is that right?13board yet?13A. I was.14A. I believe it has not been decided.14Q. How many declarations did you submitt15Q. How many European patent office15that?16A. This is the same case as Europe, so it17A. Three or four.18Q. And, again, that was as an expert in18I think in the U.S. only one.19pharmacology?19Q. And so you were you deposed only o20A. Initially, it was from my own patents,21A. Yes.	-		3	
 6 Q. Were you deposed in that case? 7 A. I was. 8 Q. Do you know if that case is still ongoing 9 or has it been resolved? 10 A. It's not settled. 11 Q. It's not. 12 Do you know it's been decided by the 13 board yet? 14 A. I believe it has not been decided. 15 Q. How many European patent office 16 proceedings have you submitted testimony? 17 A. Three or four. 18 Q. And, again, that was as an expert in 19 pharmacology? 20 A. Initially, it was from my own patents, 21 but more recently as an expert. 6 A. No, this was product. 7 Q. Product liability? 8 A. Product liability. 9 Q. Understood. Thank you. 10 So focusing on the one other IPR in which 11 you submitted testimony you said you were 12 deposed in that case; is that right? 13 A. I was. 14 Q. How many declarations did you submitted 15 that? 16 A. This is the same case as Europe, so it 17 gets it gets complicated. 18 I think in the U.S. only one. 19 Q. And so you were you deposed only on 20 in that case? 21 but more recently as an expert. 21 A. Yes. 	4			
 7 A. I was. 8 Q. Do you know if that case is still ongoing 9 or has it been resolved? 10 A. It's not settled. 11 Q. It's not. 12 Do you know it's been decided by the 13 board yet? 14 A. I believe it has not been decided. 15 Q. How many European patent office 16 proceedings have you submitted testimony? 17 A. Three or four. 18 Q. And, again, that was as an expert in 19 pharmacology? 20 A. Initially, it was from my own patents, 21 but more recently as an expert. 7 Q. Product liability? 8 A. Product liability. 9 Q. Understood. Thank you. 10 So focusing on the one other IPR in which in the U.S. only one. 19 Q. And so you were you deposed only on the interval of the transmitted test? 21 A. Yes. 	5		5	
 8 Q. Do you know if that case is still ongoing 9 or has it been resolved? 10 A. It's not settled. 11 Q. It's not. 12 Do you know it's been decided by the 13 board yet? 14 A. I believe it has not been decided. 15 Q. How many European patent office 16 proceedings have you submitted testimony? 17 A. Three or four. 18 Q. And, again, that was as an expert in 19 pharmacology? 20 A. Initially, it was from my own patents, 21 but more recently as an expert. 8 A. Product liability. 9 Q. Understood. Thank you. 10 So focusing on the one other IPR in which in the U.S. only one. 14 A. Initially, it was from my own patents, 21 but more recently as an expert. 21 A. Yes. 	6	Q. Were you deposed in that case?		*
 9 or has it been resolved? 9 Q. Understood. Thank you. 10 A. It's not settled. 11 Q. It's not. 12 Do you know it's been decided by the 13 board yet? 14 A. I believe it has not been decided. 15 Q. How many European patent office 16 proceedings have you submitted testimony? 17 A. Three or four. 18 Q. And, again, that was as an expert in 19 pharmacology? 20 A. Initially, it was from my own patents, 21 but more recently as an expert. 9 Q. Understood. Thank you. 10 So focusing on the one other IPR in which it is the same one other IPR in which it is the same one other IPR in which it is the same of the integration of the integ	7		7	
10A. It's not settled.10So focusing on the one other IPR in which11Q. It's not.11you submitted testimony you said you were12Do you know it's been decided by the11you submitted testimony you said you were13board yet?13A. I was.14A. I believe it has not been decided.14Q. How many European patent office16proceedings have you submitted testimony?16A. This is the same case as Europe, so it17A. Three or four.17gets it gets complicated.18Q. And, again, that was as an expert in19Q. And so you were you deposed only o20A. Initially, it was from my own patents,21A. Yes.			8	-
11Q. It's not.11 you submitted testimony you said you were12Do you know it's been decided by the12 deposed in that case; is that right?13board yet?13A. I was.14A. I believe it has not been decided.14Q. How many declarations did you submit15Q. How many European patent office14Q. How many declarations did you submit16A. This is the same case as Europe, so it1717A. Three or four.16A. This is the same case as Europe, so it18Q. And, again, that was as an expert in18I think in the U.S. only one.19pharmacology?19Q. And so you were you deposed only o20A. Initially, it was from my own patents,21A. Yes.			9	
12Do you know it's been decided by the13board yet?14A. I believe it has not been decided.15Q. How many European patent office16proceedings have you submitted testimony?17A. Three or four.18Q. And, again, that was as an expert in19pharmacology?20A. Initially, it was from my own patents,21but more recently as an expert.				So focusing on the one other IPR in which
13 board yet?13A. I was.14A. I believe it has not been decided.14Q. How many declarations did you submit15Q. How many European patent office14Q. How many declarations did you submit16proceedings have you submitted testimony?16A. This is the same case as Europe, so it17A. Three or four.17gets it gets complicated.18Q. And, again, that was as an expert in18I think in the U.S. only one.19pharmacology?19Q. And so you were you deposed only o20A. Initially, it was from my own patents,21A. Yes.		-		
14A. I believe it has not been decided.14Q. How many declarations did you submit15Q. How many European patent office15that was usubmitted testimony?16A. Three or four.16A. This is the same case as Europe, so it17A. Three or four.16A. This is the same case as Europe, so it18Q. And, again, that was as an expert in18I think in the U.S. only one.19pharmacology?19Q. And so you were you deposed only o20A. Initially, it was from my own patents,21A. Yes.				· ·
15Q. How many European patent office15that?16proceedings have you submitted testimony?16A. This is the same case as Europe, so it17A. Three or four.16A. This is the same case as Europe, so it18Q. And, again, that was as an expert in18I think in the U.S. only one.19pharmacology?19Q. And so you were you deposed only o20A. Initially, it was from my own patents,21A. Yes.		-		
16proceedings have you submitted testimony?16A. This is the same case as Europe, so it17A. Three or four.16A. This is the same case as Europe, so it18Q. And, again, that was as an expert in17gets it gets complicated.19pharmacology?19Q. And so you were you deposed only o20A. Initially, it was from my own patents,21hat case?21but more recently as an expert.21A. Yes.				Q. How many declarations did you submit in
17A. Three or four.17gets it gets complicated.18Q. And, again, that was as an expert in18I think in the U.S. only one.19pharmacology?19Q. And so you were you deposed only o20A. Initially, it was from my own patents,20in that case?21but more recently as an expert.21A. Yes.				
18Q. And, again, that was as an expert in18I think in the U.S. only one.19pharmacology?19Q. And so you were you deposed only o20A. Initially, it was from my own patents,20 in that case?21but more recently as an expert.2121A. Yes.				-
19 pharmacology?19 Q. And so you were you deposed only o20 A. Initially, it was from my own patents, 21 but more recently as an expert.19 Q. And so you were you deposed only o20 A. Initially, it was from my own patents, 21 but more recently as an expert.20 in that case? 21 A. Yes.				
20A. Initially, it was from my own patents,20 in that case?21 but more recently as an expert.21A. Yes.				
21 but more recently as an expert.21A. Yes.	19 pharmacology?			Q. And so you were you deposed only once
			20	
	20			A \$7
	20 21	but more recently as an expert.		
23 is that right?23 sorry who has retained you in that case?	20 21 22	but more recently as an expert. Q. You own a number of U.S. patents as well;	22	Q. And who were you working for in that
24A. That's correct.24A. Insys Pharmaceuticals.	20 21 22 23	but more recently as an expert. Q. You own a number of U.S. patents as well; is that right?	22 23	Q. And who were you working for in that sorry who has retained you in that case?
25 Q. Did you submit any written testimony in 25 Q. Who was counsel for Insys?	20 21 22 23 24	but more recently as an expert.Q. You own a number of U.S. patents as well;is that right?A. That's correct.	22 23 24	Q. And who were you working for in that sorry who has retained you in that case?A. Insys Pharmaceuticals.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.